Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 3/20 | 1.00 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.74 |
| ▸ | OSBP | P22059 | 3/20 | 0.70 |
| ▸ | USP2 | O75604 | 2/20 | 0.70 |
| ▸ | RORC | P51449 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.70 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.70 |
| ▸ | NPC1L1 | Q9UHC9 | 4/20 | 0.69 |
| ▸ | CDC25A | P30304 | 1/20 | 0.64 |
| ▸ | GBA1 | P04062 | 2/20 | 0.63 |
| ▸ | UGCG | Q16739 | 2/20 | 0.63 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.63 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.63 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.63 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15110118 | 1.00 | POLA1 (1.00) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL587901 | 1.00 | POLA1 (1.00) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL16306859 | 1.00 | POLA1 (1.00) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL13147079 | 1.00 | POLA1 (1.00) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL1708156 | 1.00 | POLA1 (1.00) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL15398207 | 0.93 | POLA1 (0.87) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL12947846 | 0.93 | POLA1 (0.87) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL5009864 | 0.93 | POLA1 (0.86) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL16790328 | 0.93 | POLA1 (0.86) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL2474688 | 0.93 | POLA1 (0.86) | POLA1CYP46A1OSBPUSP2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2802556-A1 | LIPOPOLYAMINES OF SPERMINE TYPE FOR CONSTRUCTION OF LIPOSOMAL TRANSFECTION SYSTEMS | Ustav Organicke Chemie A Biochemie Av Cr, V.v.i. (CZ) | 2014-11-19 | — | — | EP | disclosed |
| US-8618242-B2 | Photo-activated attachment of cholesterol to polyurethane surfaces for adhesion of endothelial cells | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2013-12-31 | — | — | US | disclosed |
| WO-2013104346-A1 | LIPOPOLYAMINES OF SPERMINE TYPE FOR CONSTRUCTION OF LIPOSOMAL TRANSFECTION SYSTEMS | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2013-07-18 | — | — | WO | disclosed |
| US-20120089222-A1 | Photo-Activated Attachment Of Cholesterol To Polyurethane Surfaces For Adhesion Of Endothelial Cells | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2012-04-12 | — | — | US | disclosed |
| EP-2416658-A1 | PHOTO-ACTIVATED ATTACHMENT OF CHOLESTEROL TO POLYURETHANE SURFACES FOR ADHESION OF ENDOTHELIAL CELLS | The Children's Hospital Of Philadelphia (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2011120053-A1 | MODIFIED POLYMERS FOR DELIVERY OF POLYNUCLEOTIDES, METHOD OF MANUFACTURE, AND METHODS OF USE THEREOF | MERSANA THERAPEUTICS, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2010118306-A1 | PHOTO-ACTIVATED ATTACHMENT OF CHOLESTEROL TO POLYURETHANE SURFACES FOR ADHESION OF ENDOTHELIAL CELLS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2010-10-14 | — | — | WO | disclosed |
| US-7455856-B2 | Lipid-derivatized bisphosphonic acid | MCS MICRO CARRIER SYSTEMS GMBH (DE) | 2008-11-25 | — | — | US | disclosed |
| US-20070154537-A1 | Lipid-derivatized bisphosphonic acid | MCS MICRO CARRIER SYSTEMS GMBH (DE) | 2007-07-05 | — | — | US | disclosed |
| US-5152999-A | Adriamycin entrapped cholesterol derivatives having a negative charge | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-06 | — | — | US | disclosed |
| EP-0237051-B1 | PRODRUG COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND SUSTAINED RELEASE PREPARATION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| US-4772594-A | ANTITUMOR, CHOLESTEROL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-09-20 | — | — | US | disclosed |
| EP-0237051-A2 | Prodrug compounds, process for the preparation thereof and sustained release preparation comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070154537-A1 | Lipid-derivatized bisphosphonic acid | SGMS1, PHOSPHO1, SGMS2 | POLA1 3262/4885CYP46A1 309/4885OSBP 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.